Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29136923 | 1.00 | CA12 (0.41) | CA12CA1CA2TYRCA7 | |
| SCHEMBL6296330 | 0.77 | NLRP3 (0.39) | KMT2AMEN1ALDH1A1NLRP3TGFBR1 | |
| SCHEMBL6296329 | 0.77 | NLRP3 (0.39) | KMT2AMEN1ALDH1A1NLRP3TGFBR1 | |
| SCHEMBL24149773 | 0.77 | TGFBR1 (0.39) | KMT2AMEN1ALDH1A1NLRP3TGFBR1 | |
| SCHEMBL5671760 | 0.73 | HDAC1 (0.52) | CA12CA1CA2TYRCA7 | |
| SCHEMBL5671756 | 0.73 | HDAC1 (0.52) | CA12CA1CA2TYRCA7 | |
| SCHEMBL7301257 | 0.71 | JAK2 (0.50) | CA12CA1CA2TYRCA7 | |
| SCHEMBL7301264 | 0.71 | JAK2 (0.50) | CA12CA1CA2TYRCA7 | |
| SCHEMBL19836882 | 0.71 | MAPT (0.34) | ALDH1A1NLRP3TGFBR1SMN1; SMN2KDM4E | |
| SCHEMBL19836880 | 0.71 | MAPT (0.34) | ALDH1A1NLRP3TGFBR1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4585265-A2 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| EP-4308230-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-20230285372-A1 | Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives | MEDCURIUS INC. (CN) | 2023-09-14 | — | — | US | disclosed |
| US-20230285372-A1 | Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives | MEDCURIUS INC. (CN) | 2023-09-14 | — | — | US | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2021259143-A1 | PHARMACEUTICAL USE OF (E)-3-ARYLHETEROCYCLYL PROP-2-ENOIC ACID DERIVATIVES | 上海长车生物科技有限公司 | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | CA12 4065/4885CA1 4077/4885CA2 4351/4885 |
| US-20230285372-A1 | Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives | NFE2L2, NFE2, TXNRD2 | CA12 4585/4885CA1 4310/4885CA2 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.